| scholarly article | Q13442814 |
| P2093 | author name string | Richard I Christopherson | |
| Stephen P Mulligan | |||
| Larissa Belov | |||
| Swetlana Mactier | |||
| Pauline Huang | |||
| Carlos Cassano | |||
| P2860 | cites work | CD43-mediated signals induce DNA binding activity of AP-1, NF-AT, and NFkappa B transcription factors in human T lymphocytes | Q28141639 |
| Cladribine induces apoptosis in human leukaemia cells by caspase-dependent and -independent pathways acting on mitochondria | Q28362384 | ||
| Cladribine in the treatment of chronic lymphocytic leukemia | Q33337860 | ||
| Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia | Q33344749 | ||
| Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies. | Q33361984 | ||
| Cytotoxic drugs and the CD95 pathway | Q33771744 | ||
| Morphological and virological investigations on cultured Burkitt tumor lymphoblasts (strain Raji). | Q34205569 | ||
| Novel therapies for chronic lymphocytic leukemia | Q34304235 | ||
| Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia | Q34402999 | ||
| Impaired transendothelial migration of B-CLL lymphocytes: a defect linked to low L-selectin expression | Q34431467 | ||
| Epratuzumab: targeting B-cell malignancies through CD22 | Q35541773 | ||
| Analysis of human leukaemias and lymphomas using extensive immunophenotypes from an antibody microarray. | Q50717432 | ||
| Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153. | Q53246385 | ||
| 2-Chlorodeoxyadenosine treatment in non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia resistant to conventional chemotherapy: results of a multicentric experience. International Society for Chemo-Immunotherapy. | Q53366338 | ||
| Localization in situ of costimulatory molecules and cytokines in B-cell non-Hodgkin's lymphoma | Q56907624 | ||
| CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by up-regulation of CD80 and CD86 costimulatory molecules | Q56908513 | ||
| Comparative effects of cladribine, fludarabine and pentostatin on nucleotide metabolism in T- and B-cell lines | Q57364347 | ||
| Phase III Intergroup Study of Fludarabine Phosphate Compared With Cyclophosphamide, Vincristine, and Prednisone Chemotherapy in Newly Diagnosed Patients With Stage III and IV Low-Grade Malignant Non-Hodgkin's Lymphoma | Q60685422 | ||
| Chronic lymphocytic leukemia | Q72059563 | ||
| Expression of CD10 by human T cells that undergo apoptosis both in vitro and in vivo | Q73168635 | ||
| CD22 ligand binding regulates normal and malignant B lymphocyte survival in vivo | Q80142486 | ||
| All-trans retinoic acid induces different immunophenotypic changes on human HL60 and NB4 myeloid leukaemias | Q80461863 | ||
| Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma | Q81919524 | ||
| Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era. | Q35739922 | ||
| Monoclonal antibodies in the treatment of chronic lymphoid leukemias | Q35752823 | ||
| Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies | Q36057860 | ||
| Immunotoxins in the treatment of hematologic malignancies | Q36638455 | ||
| Molecular mechanisms involved in CD43-mediated apoptosis of TF-1 cells. Roles of transcription Daxx expression, and adhesion molecules | Q38293363 | ||
| Differential roles of STAT1alpha and STAT1beta in fludarabine-induced cell cycle arrest and apoptosis in human B cells | Q38339660 | ||
| Characterization of a CD43/leukosialin-mediated pathway for inducing apoptosis in human T-lymphoblastoid cells | Q38351915 | ||
| Levels of expression of CD19 and CD20 in chronic B cell leukaemias | Q39594937 | ||
| Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity | Q40259744 | ||
| Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma. | Q40329298 | ||
| Overexpression of leukocyte marker CD43 causes activation of the tumor suppressor proteins p53 and ARF. | Q40607190 | ||
| Production and the characterization of monoclonal antibody against CD43, K06. | Q40611271 | ||
| Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma | Q40765965 | ||
| Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. | Q40779596 | ||
| 2-Chloro-2'-deoxyadenosine induces apoptosis through the Fas/Fas ligand pathway in human leukemia cell line MOLT-4. | Q40900193 | ||
| MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation | Q42820324 | ||
| Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia | Q43904550 | ||
| Activation of a p53-mediated apoptotic pathway in quiescent lymphocytes after the inhibition of DNA repair by fludarabine | Q44545594 | ||
| Expression of CD10 by B-chronic lymphocytic leukemia cells undergoing apoptosis in vivo and in vitro. | Q44560554 | ||
| Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. | Q44892386 | ||
| Immunophenotypic changes induced on human HL60 leukaemia cells by 1alpha,25-dihydroxyvitamin D3 and 12-O-tetradecanoyl phorbol-13-acetate | Q46659619 | ||
| Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis | Q47745198 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P304 | page(s) | 964251 | |
| P577 | publication date | 2010-05-05 | |
| P1433 | published in | International Journal of Proteomics | Q26842889 |
| P1476 | title | Cladribine and Fludarabine Nucleoside Change the Levels of CD Antigens on B-Lymphoproliferative Disorders | |
| P478 | volume | 2010 |
| Q36907112 | BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells. |
| Q39434653 | Fludarabine nucleoside modulates nuclear "survival and death" proteins in resistant chronic lymphocytic leukemia cells |
| Q34177843 | Targeting mTORC1-mediated metabolic addiction overcomes fludarabine resistance in malignant B cells. |
| Q34747359 | Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia |
Search more.